173 related articles for article (PubMed ID: 29869398)
1. Editorial Comment from Dr Chapple to Long-term safety and efficacy of the novel β
Chapple CR
Int J Urol; 2018 Jul; 25(7):677. PubMed ID: 29869398
[No Abstract] [Full Text] [Related]
2. Editorial Comment from Dr Yamanishi to Long-term safety and efficacy of the novel β
Yamanishi T
Int J Urol; 2018 Jul; 25(7):676. PubMed ID: 29862577
[No Abstract] [Full Text] [Related]
3. Long-term safety and efficacy of the novel β
Yoshida M; Kakizaki H; Takahashi S; Nagai S; Kurose T
Int J Urol; 2018 Jul; 25(7):668-675. PubMed ID: 29752752
[TBL] [Abstract][Full Text] [Related]
4. Editorial Comment to Efficacy of novel β
Kitta T
Int J Urol; 2019 Mar; 26(3):375-376. PubMed ID: 30557905
[No Abstract] [Full Text] [Related]
5. Vibegron, a Novel Potent and Selective β
Yoshida M; Takeda M; Gotoh M; Nagai S; Kurose T
Eur Urol; 2018 May; 73(5):783-790. PubMed ID: 29366513
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of novel β
Yoshida M; Takeda M; Gotoh M; Yokoyama O; Kakizaki H; Takahashi S; Masumori N; Nagai S; Hashimoto K; Minemura K
Int J Urol; 2019 Mar; 26(3):369-375. PubMed ID: 30557916
[TBL] [Abstract][Full Text] [Related]
7. Re: Vibegron, a Novel Potent and Selective β3-Adrenoreceptor Agonist, for the Treatment of Patients with Overactive Bladder: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study.
Wein AJ
J Urol; 2019 Aug; 202(2):218. PubMed ID: 31075074
[No Abstract] [Full Text] [Related]
8. Pharmacological Characterization of a Novel Beta 3 Adrenergic Agonist, Vibegron: Evaluation of Antimuscarinic Receptor Selectivity for Combination Therapy for Overactive Bladder.
Di Salvo J; Nagabukuro H; Wickham LA; Abbadie C; DeMartino JA; Fitzmaurice A; Gichuru L; Kulick A; Donnelly MJ; Jochnowitz N; Hurley AL; Pereira A; Sanfiz A; Veronin G; Villa K; Woods J; Zamlynny B; Zycband E; Salituro GM; Frenkl T; Weber AE; Edmondson SD; Struthers M
J Pharmacol Exp Ther; 2017 Feb; 360(2):346-355. PubMed ID: 27965369
[TBL] [Abstract][Full Text] [Related]
9. Vibegron: a β
Paton DM
Drugs Today (Barc); 2021 Aug; 57(8):507-517. PubMed ID: 34405208
[TBL] [Abstract][Full Text] [Related]
10. Discovery of Vibegron: A Potent and Selective β3 Adrenergic Receptor Agonist for the Treatment of Overactive Bladder.
Edmondson SD; Zhu C; Kar NF; Di Salvo J; Nagabukuro H; Sacre-Salem B; Dingley K; Berger R; Goble SD; Morriello G; Harper B; Moyes CR; Shen DM; Wang L; Ball R; Fitzmaurice A; Frenkl T; Gichuru LN; Ha S; Hurley AL; Jochnowitz N; Levorse D; Mistry S; Miller RR; Ormes J; Salituro GM; Sanfiz A; Stevenson AS; Villa K; Zamlynny B; Green S; Struthers M; Weber AE
J Med Chem; 2016 Jan; 59(2):609-23. PubMed ID: 26709102
[TBL] [Abstract][Full Text] [Related]
11. Vibegron (Gemtesa) for overactive bladder.
Med Lett Drugs Ther; 2021 May; 63(1623):67-69. PubMed ID: 33976098
[No Abstract] [Full Text] [Related]
12. Vibegron: First Global Approval.
Keam SJ
Drugs; 2018 Nov; 78(17):1835-1839. PubMed ID: 30411311
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular safety of vibegron, a new β3-adrenoceptor agonist, in older patients with overactive bladder: Post-hoc analysis of a randomized, placebo-controlled, double-blind comparative phase 3 study.
Yoshida M; Takeda M; Gotoh M; Yokoyama O; Kakizaki H; Takahashi S; Masumori N; Nagai S; Minemura K
Neurourol Urodyn; 2021 Aug; 40(6):1651-1660. PubMed ID: 34139038
[TBL] [Abstract][Full Text] [Related]
14. Vibegron inhibits enhanced spontaneous contractions induced by anoxia/reoxygenation in isolated whole bladder from rats.
Ikeda M; Nakada A; Abukawa H; Yamazaki T; Maruyama I
Eur J Pharmacol; 2022 Jul; 926():175017. PubMed ID: 35588870
[TBL] [Abstract][Full Text] [Related]
15. Re: Efficacy of the novel selective β3-adrenoreceptor agonist vibegron for treatment-resistant monosymptomatic nocturnal enuresis in children.
Nishizaki N; Morishita T
Int J Urol; 2020 Dec; 27(12):1161. PubMed ID: 32808378
[No Abstract] [Full Text] [Related]
16. Efficacy of the novel selective β3-adrenoreceptor agonist vibegron for treatment-resistant monosymptomatic nocturnal enuresis in children.
Fujinaga S; Watanabe Y; Nakagawa M
Int J Urol; 2020 Aug; 27(8):693-694. PubMed ID: 32430925
[No Abstract] [Full Text] [Related]
17. Pharmacokinetics and Safety of Vibegron 75 mg Administered as an Intact or Crushed Tablet in Healthy Adults.
King J; Walker A; Aikin D; Haag-Molkenteller C; Kankam M
Clin Pharmacol Drug Dev; 2022 Nov; 11(11):1349-1355. PubMed ID: 36104302
[TBL] [Abstract][Full Text] [Related]
18. Effects of the combination of vibegron and imidafenacin on bladder function in urethane-anesthetized rats.
Yamazaki T; Maruyama I
Eur J Pharmacol; 2019 Dec; 864():172727. PubMed ID: 31600494
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of vibegron, a novel β3-adrenoreceptor agonist, for lower urinary tract dysfunction in mice with spinal cord injury.
Shimizu N; Gotoh D; Nishimoto M; Hashimoto M; Saito T; Fujita K; Hirayama A; Yoshimura N; Uemura H
Int J Urol; 2021 Oct; 28(10):1068-1072. PubMed ID: 34272910
[TBL] [Abstract][Full Text] [Related]
20. Vibegron 50 mg is the optimal algorithm in the pharmacologic management of overactive bladder: outcomes from a systematic review and meta-analysis.
Jian Z; Yuan C; Li H; Zhang W; Wang K
Int Urol Nephrol; 2020 Dec; 52(12):2215-2221. PubMed ID: 32519241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
